Virtual Library

Start Your Search

Jingjing Qu

Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      133P - A study evaluating the different treatment modalities for EGFR mutation positive advanced NSCLC patients that acquire c-MET amplification after EGFR TKI therapy resistant (ID 176)

      12:30 - 13:00  |  Presenting Author(s): Jingjing Qu

      • Abstract
      • Slides


      c-MET amplification was one of the major important mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Whereas, once the patient acquired c-MET amplification combined with EGFR mutation after EGFR-TKI resistant, the most optimal treatment strategy is remains controversial. Our study proposed an optimal treatment strategy for EGFR mutant NSCLC patients who acquired c-MET amplification after EGFR TKI resistance.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      Patients with EGFR mutant NSCLC acquiring c-MET amplification, detected from a re-biopsy performed after progression on EGFR-TKI, were identified in Hunan Cancer Hospital. Clinical data were retrospectively collected.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      Between March 2015 and July 2018, 393 patients were screened and 30 of them were enrolled. EGFR status prior to the initiation of first line therapy was not associated with sex, age and smoking status. After patients developed resistance to EGFR-TKI, the re-biopsy was performed. 30 patients with c-MET amplification and EGFR mutation and received different treatment. The median PFS between c-MET inhibitors(c-METi) combined EGFR-TKI versus c-MET inhibitors were 4.0 months and 1.5 months (HR:0.07; 95% CI, 0.01 to 0.35; P = 0.003), respectively. The PFS in the chemotherapy group was 3.0m and without significance compared to c-METi combined EGFR-TKI group or c-METi monotherapy group. The objective response rates for patients treated with a combination of c-METi and EGFR-TKI, chemotherapy alone and c-METi alone were 58.8%, 14.3% and 16.7%, respectively.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      This study, comparing the ORR and PFS of EGFR-mutant patients after acquiring c-MET as the major resistance of EGFR-TKI, suggests that a combination of c-METi and EGFR-TKI maybe the best optimal treatment.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      Hunan Provincial Tumor Hospital.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.